ARGENX SE Business Summary

argenx SE (ARGX) is a commercial-stage biotechnology leader that generates revenue primarily through global product net sales of its neonatal Fc receptor (FcRn) blocker franchise, Vyvgart (efgartigimod) and Vyvgart Hytrulo. The company operates within the precision immunology segment, focusing on antibody-based medicines for severe autoimmune diseases such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). In 2025, argenx achieved its first year of operating profitability, reporting $4.2 billion in product net sales—a 90% year-over-year increase—driven by its "pipeline-in-a-product" strategy that leverages its SIMPLE Antibody platform to expand into over 10 indications. Within the competitive landscape, argenx maintains a dominant 65%+ market share in the FcRn inhibitor space, positioned as the first-mover and best-in-class incumbent against direct rivals including Johnson & Johnson (nipocalimab), UCB (Rystiggo), and Immunovant (IMVT-1402), as well as established biologics like AstraZeneca’s Ultomiris. argenx was founded in 2008 by a veteran trio of life science professionals: Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier. As of February 2026, the executive leadership is led by co-founder and CEO Tim Van Hauwermeiren, who is currently managing a transition to Chairman of the Board (effective May 2026), with current COO Karen Massey—formerly of Genentech—serving as CEO-elect. The management team includes Karl Gubitz (CFO), Peter Ulrichts (CSO), Luc Truyen (CMO), and Sandrine Piret-Gérard, who was appointed Chief Commercialization Officer in early 2026. The company is governed by a board chaired by Peter Verhaeghe and includes notable directors such as Camilla Sylvest (formerly of Novo Nordisk) and Tony Rosenberg. argenx is backed by a robust institutional investor base, including Life Sciences Partners (LSP) and Omnes Capital, and maintains a fortress balance sheet with approximately $3.8 billion in cash reserves.